Leading the Next Revolution in Cell Therapy

Allogene THERAPEUTICS

Allogene is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Allogeneic CAR T therapies are engineered from the T cells of healthy donors. These "off-the-shelf" CAR T therapies enhanced by gene editing could be the next most important breakthrough in the field.

Allogene is attempting to overcome the limitations of autologous CAR T (AutoCAR T™) therapies by creating allogeneic CAR T cell therapies (AlloCAR T™ or AlloCARs™). Unlike AutoCAR T™, AlloCAR T™ therapy uses T cells from healthy donors, modified using gene editing to limit an immune response when given to a patient different than the donor. These therapies are then stored in cryopreserved vials for "on-demand" delivery to patients.

AlloCAR T™ therapy has the potential to revolutionize cancer treatment by improving:

SPEED TO PATIENT

- Product delivery on demand from inventory
- Faster time to treatment may improve patient outcomes

ENHANCED CELL POTENCY

- More uniform starting materials sourced from healthy donors
- Potential for more predictable safety and efficacy

EFFICIENCIES

- Potential to treat ~100 patients from a single manufacturing run
- Ability to scale production to further reduce cost

AVAILABILITY AND ACCESS

- "Off-the-shelf" product enables creation of inventory
- Potential to treat all eligible patients
- Retreatment ease

Applying Innovative Technology to Develop AlloCAR T™ Therapy

The process for manufacturing our off-the-shelf AlloCAR T™ therapy first involves collecting white blood cells from healthy donors. The collected cells are then screened, tested, and shipped to a central processing facility, where the T cells are isolated and stored frozen, creating an inventory of healthy donor cells for manufacturing. This means that a larger portion of eligible patients, including those who are critically ill and have T cells that are difficult to harvest or expand, can potentially receive treatment, without having to undergo leukapheresis (a laboratory procedure in which a patient's white blood cells are separated and the remaining blood cells and plasma are returned to the patient).

Next, the T cells are engineered to express CARs, which recognize certain cell surface proteins that are expressed in hematologic or solid tumors. ALLO-501 and UCART19, two of our investigational therapies, target CD19, while a third, ALLO-715, targets BCMA, cell surface proteins expressed on B-cells, including cancerous B-cells. These are just the first in a line of AlloCAR T™ therapies we plan to develop. The next step in the process involves gene editing to reduce the risk of graft versus host disease (GvHD) and allogeneic rejection. A T cell receptor gene is knocked out to avoid GvHD. The CD52 gene is knocked out to render the CAR T product resistant to anti-CD52 antibody treatment. ALLO-647, our proprietary anti-CD52 monoclonal antibody, can therefore be used to suppress the host immune system and potentially allow the AlloCAR T™ to stay engrafted to achieve full therapeutic impact.

The engineered T cells then undergo a purification step and are ultimately cryopreserved in vials for delivery to patients.

COMPANY INFORMATION

- First company, **jointly with Servier**, with clinical **AlloCAR T™** therapy data (UCART19/Servier Sponsored)
- **ALLO-501**: Phase 1 R/R NHL
- **ALLO-715**: Phase 1 R/R MM
- **UCART19:** Phase 1 Adult and Pediatric R/R ALL (Servier Sponsored)
- Pipeline: 14 additional tumor targets
- Building state-of-the-art manufacturing facility in **Newark, CA**
- Headquartered in **South San Francisco**, with offices in **New York**

FINANCIAL OVERVIEW

- NASDAQ: **ALLO**
- Completed a **$343 million** IPO in October 2018, one of the largest in biotechnology
- Total capital raised since inception in 2018: **$793 million**
- Market Cap: **~$3.5B**
- Shares Outstanding: **122 million** as of Nov 1, 2019

OUR LEADERS

Our world-class management team has unrivaled experience.

Arie Belldegrun, M.D., FACS
Executive Chairman & Co-Founder
Kite · UroGen Pharma · Agensys

David Chang, M.D., Ph.D.
President, CEO & Co-Founder
Kite · AMGEN

Alison Moore, Ph.D.
Chief Technical Officer
AMGEN · Genentech

Barbra Sasu, Ph.D.
Chief Scientific Officer
Pfizer · AMGEN

Christine Cassiano
Chief Communications Officer
Kite · AMGEN · Allergan

Eric Schmidt, Ph.D.
Chief Financial Officer
COWEN · UBS

Rafael Amado, M.D.
EVP of R&D, Chief Medical Officer
Adaptimmune · AMGEN · GSK

Susie Jun, M.D., Ph.D.
Chief Development Officer
abbvie · AMGEN · GILEAD

Veer Bhavnagri
General Counsel
Kite · Cooley · SULLIVAN & CROMWELL LLP

Deep AlloCAR T™ Pipeline Targets A Vast Array of Tumor Types, With Two Candidates in Clinic

Our AlloCAR T™ portfolio includes rights to 14 pre-clinical CAR T cell therapy targets and clinical candidates ALLO-501, UCART19 and ALLO-715.

CATEGORY	PROGRAM	PRE-CLINICAL	PHASE 1	PHASE 2/3[1]
Hematological Malignancies	**UCART19 (CD19/ALL)**[2] (Servier Sponsored)			
	ALLO-501 (CD19/NHL)[2]			
	ALLO-715 (BCMA/MM)			
	ALLO-819 (FLT3/AML)			
	CD70 (Hematological Malignancies)			
Solid Tumors	**CD70 (RCC)**			
	DLL3 (SCLC)			
Lymphodepletion Agent	**ALLO-647** (Anti-CD52 mAb)[3]			

[1] Phase 3 may not be required if Phase 2 is registrational
[2] Servier holds ex-US commercial rights
[3] ALLO-647 intended to enable expansion and persistence of allogeneic CAR T product candidates
11 Additional Tumor Targets in Preclinical Research

State-of-the-Art, In-House Manufacturing for Long-Term Clinical and Commercial AlloCAR T™ Production

Building world-class manufacturing capabilities is at the core of our strategy to deliver readily available AlloCARs™ faster, more reliably and at greater scale.

A new manufacturing facility, located in Newark, CA, in San Francisco's East Bay Area, is being designed to provide GMP manufacturing for clinical supply and commercial product upon potential regulatory approval, and will complement Allogene's buildout of in-house process development and characterization capabilities.

Allogene currently manufactures its clinical trial supply through a contract manufacturing organization, which remains a component of our long-term manufacturing strategy.

- UCART19 and ALLO-501 are being jointly developed under a clinical development collaboration between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. UCART19 and ALLO-501 utilize TALEN® gene-editing technology pioneered and owned by Cellectis. Both UCART19 and ALLO-501 feature the same construct but are manufactured using a different process. The UCART19 clinical program for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL) is sponsored by Servier. The ALLO-501 clinical program for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) is sponsored by Allogene. Servier grants to Allogene exclusive rights to UCART19 and ALLO-501 in the U.S. while Servier retains exclusive rights for all other countries.
- ALLO-715 utilizes the TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the BCMA target. Allogene holds the global development and commercial rights for this investigational candidate.
- ALLO-819 utilizes the TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the FLT3 target. Allogene holds the global development and commercial rights for this investigational candidate.
- The CD70 pre-clinical constructs utilize the TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the CD70 target. Allogene holds the global development and commercial rights for this investigational candidate.

Allogene THERAPEUTICS

210 E. Grand Avenue, South San Francisco, CA 94080
Contact Allogene: info@allogene.com